Page last updated: 2024-12-07
1-cyano-3,4-epithiobutane
Description
1-cyano-3,4-epithiobutane is a **hypothetical molecule** that **does not exist**.
Here's why:
* **Chemical Structure:** The name suggests a molecule with a cyano group (-CN) at position 1, an epithio group (-S-) bridging positions 3 and 4, and a butane backbone (4 carbon chain). However, **epithio groups cannot bridge carbons that are three atoms apart.** They require adjacent carbons to form a three-membered ring.
* **Strain:** If the epithio group were to be forced onto positions 3 and 4, it would introduce significant ring strain due to the small size of the ring and the angle constraints. This high energy state would make the molecule unstable and unlikely to exist.
Therefore, **1-cyano-3,4-epithiobutane is not a valid chemical structure.**
**Possible Misunderstandings:**
It's possible the name was intended for a different molecule, perhaps with a different arrangement of the functional groups or a different backbone structure.
**If you have the correct structure, please provide it, and I can help explain its importance in research.**
1-cyano-3,4-epithiobutane: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 100582 |
| CHEBI ID | 193948 |
| SCHEMBL ID | 3500243 |
| MeSH ID | M0173019 |
Synonyms (22)
| Synonym |
|---|
| nsc-322064 |
| nsc322064 |
| 54096-45-6 |
| cyano-3,4-epithiobutane |
| brn 1362236 |
| 4,5-epithiovaleronitrile |
| valeronitrile, 4,5-epithio- |
| 1-cyano-3,4-epithiobutane |
| nsc 322064 |
| thiiranepropanenitrile |
| 76786-81-7 |
| 3-(thiiran-2-yl)propanenitrile |
| CHEBI:193948 |
| AKOS006276486 |
| thiiranepropanenitrile, (+-)- |
| 5-18-06-00016 (beilstein handbook reference) |
| SCHEMBL3500243 |
| ZAGXORSINWAUSP-UHFFFAOYSA-N |
| thiiranepropanenitrile, 9ci |
| 4,5-epithio-valeronitrile |
| (+-)-thiiranepropanenitrile |
| DTXSID10998106 |
Drug Classes (2)
| Class | Description |
|---|
| saturated organic heteromonocyclic parent | |
| organosulfur heterocyclic compound | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (3)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.53
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.53 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.32 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |